Search results
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time...
Motley Fool via Yahoo Finance· 2 hours agoShares of Structure Therapeutics (NASDAQ: GPCR) shot up more than 50% during the first week of June....
Here’s Why Viking Therapeutics (VKTX) Shares Rose in Q1
Insider Monkey via Yahoo Finance· 22 minutes agoBaron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter...
Sage Therapeutics' rare disease drug meets main goal in mid-stage study
Reuters via Yahoo News· 23 minutes ago(Reuters) - Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington's disease ...
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 1,133 Shares
ETF DAILY NEWS· 6 hours agoEnliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 1,133 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold ...
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $64.86
ETF DAILY NEWS· 8 hours agoArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the ...
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of “Hold” by Analysts
ETF DAILY NEWS· 9 hours agoFate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has earned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat ...
Enliven Therapeutics COO sells over $22k in company stock By Investing.com
Investing.com· 12 hours agoEnliven Therapeutics, Inc. (NASDAQ:ELVN) has reported a recent transaction involving its Chief...
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com
Investing.com· 12 hours agoDirector of Rapport Therapeutics, Inc. (NASDAQ:RAPP), James Healy, has recently made a substantial...
Wolfe Research bullish on Akero stock, cites NASH treatment potential By Investing.com
Investing.com· 2 hours agoOn Tuesday, Wolfe Research initiated coverage on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) stock with...
With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional...
Simply Wall St. via Yahoo Finance· 18 hours agoKey Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is...